WeTrials
Recruiting

A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors

What is this study?

This study tests an investigational pill called NST-628 for adults with advanced solid tumors that have specific genetic changes. Researchers want to see if this new medicine is safe, how the body processes it, and if it can help fight cancer when other treatments have stopped working.

Who can participate?

You may be able to join if you are 18 or older with an advanced solid tumor where standard treatments are no longer an option. However, you must be able to swallow and absorb pills by mouth, and have no history of certain serious heart or eye conditions.

What will happen?

Participants will take the NST-628 study drug orally in tablet form as part of a safety and dosage evaluation. Your health team will closely monitor you throughout the study to check for side effects and see how your body responds to the treatment.

Where and when?

The study is currently recruiting participants at medical centers in San Francisco and Los Angeles, California, as well as in Denver, Colorado.

Key Points
  • 1Testing a new oral pill called NST-628 for advanced solid tumors
  • 2Designed for adults who have tried standard treatments without success
  • 3Currently recruiting patients at select locations in California and Colorado

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
OncologyMEK MutationRAF Gene MutationRas (KRAS or NRAS) Gene MutationMelanomaNSCLCGliomaSolid Tumor, AdultMAPK Pathway Gene Mutation

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.